Peroxisome proliferator-activated receptor gamma (PPAR-γ) (PPAR-γ)

Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a ligand-activated nuclear receptor and transcription factor that serves as a master regulator of adipogenesis, glucose homeostasis, and lipid metabolism [1, 6, 12]. It is predominantly expressed in adipose tissue, where it promotes the differentiation of preadipocytes into mature adipocytes and enhances the storage of fatty acids, thereby reducing lipotoxicity in peripheral tissues [6, 12, 20]. In the context of disease, PPAR-γ is a central player in the pathogenesis of type 2 diabetes and metabolic syndrome, as its activation significantly improves insulin sensitivity [3, 5, 22]. Pharmacologically, PPAR-γ is the primary target of the thiazolidinedione (TZD) class of antidiabetic drugs, such as pioglitazone and rosiglitazone, which act as potent agonists [1, 8, 10]. These drugs facilitate glucose uptake and modulate the expression of adipokines like adiponectin [7, 12, 20]. However, therapeutic use is often limited by significant safety concerns, including weight gain, fluid retention, and an increased risk of congestive heart failure and bone fractures [1, 7, 17, 21].

Other names

PPARGNR1C3Nuclear receptor subfamily 1 group C member 3Glitazone reverse insulin resistance receptorPPAR-gamma

PPAR-γ acts as a ligand-activated transcription factor that, upon agonist binding, forms a heterodimer with the Retinoid X Receptor (RXR). This complex binds to specific DNA sequences known as Peroxisome Proliferator Response Elements (PPREs) in the promoter regions of target genes, recruiting co-activators to modulate the transcription of genes involved in lipid and glucose metabolism [1, 6, 16, 18].